The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Nov. 10, 2009
Filed:
Sep. 22, 2006
Andreas Huth, Berlin, DE;
Ludwig Zorn, Berlin, DE;
Martin Kruger, Berlin, DE;
Stuat Ince, Berlin, DE;
Karl-heinz Thierauch, Berlin, DE;
Andreas Menrad, Berlin, DE;
Martin Haberey, Berlin, DE;
Holger Hess-stumpp, Berlin, DE;
Andreas Huth, Berlin, DE;
Ludwig Zorn, Berlin, DE;
Martin Kruger, Berlin, DE;
Stuat Ince, Berlin, DE;
Karl-Heinz Thierauch, Berlin, DE;
Andreas Menrad, Berlin, DE;
Martin Haberey, Berlin, DE;
Holger Hess-Stumpp, Berlin, DE;
Bayer Schering Pharma Aktiengesellschaft, Berlin, DE;
Abstract
VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridinamides, their production and use as pharmaceutical agents for treating diseases that are triggered by persistent angiogenesis, as well as intermediate products for the production of the compounds are described. The compounds according to the invention can be used as or in the case of tumor or metastasis growth, psoriasis, Kaposi's sarcoma, restenosis, such as, e.g., stent-induced restenosis, endometriosis, Crohn's disease, Hodgkin's disease, leukemia; arthritis, such as rheumatoid arthritis, hemangioma, angiofibroma; eye diseases, such as diabetic retinopathy, neovascular glaucoma; renal diseases, such as glomerulonephritis, diabetic nephropathy, malignant nephrosclerosis, thrombic microangiopathic syndrome, transplant rejections and glomerulopathy; fibrotic diseases, such as cirrhosis of the liver, mesangial cell proliferative diseases, arteriosclerosis, injuries to nerve tissue, and inhibition of the reocclusion of vessels after balloon catheter treatment, in vascular prosthetics or after mechanical devices are used to keep vessels open, such as, e.g., stents, as immunosuppressive agents, as a support in scar-free healing, senile keratosis and contact dermatitis. The compounds according to the invention can also be used as VEGFR-3 inhibitors in the case of lymphangiogenesis.